跳至主要内容
临床试验/JPRN-UMIN000016782
JPRN-UMIN000016782已完成未知

An exploratory study of treatment sensitivity and prognostic factors in a Phase III, randomized, controlled study comparing the efficacy and safety of mFOLFOX6 + bevacizumab therapy vs. mFOLFOX6 + panitumumab therapy in patients with chemotherapy-naïve wild-type RAS(KRAS/NRAS) unresectable advanced or recurrent colorectal cancer - Exploratory analysis of biomarkers in PARADIGM study

Takeda Pharmaceutical Company Limited0 个研究点目标入组 757 人开始时间: 2015年3月23日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
757

研究概览

简要总结

A

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 80years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • (1)Patients who are determined by the investigator or researchers to be not suitable for participating in the additional study

研究者

相似试验